Opinion|Videos|March 12, 2026
How Selinexor Plus Ruxolitinib Could Affect Frontline Myelofibrosis Management
Author(s)Prithviraj Bose, MD, Pankit Vachhani, MD
Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss how selinexor plus ruxolitinib could affect the frontline myelofibrosis treatment paradigm.
Advertisement
Episodes in this series
Prithviraj Bose, MD, and Pankit Vachhani, MD, explore how positive results from the phase 3 SENTRY trial (NCT04562389) could influence the frontline treatment paradigm for myelofibrosis. Bose discusses the potential for combination therapy with selinexor (Xpovio) plus ruxolitinib (Jakafi) to move beyond symptom control toward disease modification. Vachhani considers patient populations that may derive the greatest benefit and how treatment sequencing strategies could evolve.
Advertisement
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
5